Stryker Corporation is a leading medical technology company that specializes in designing, manufacturing, and marketing innovative products and services for healthcare professionals and patients. The company offers a diverse range of medical devices, including surgical equipment, orthopedic implants, neurotechnology, and surgery assistance products. Stryker focuses on advancing healthcare through cutting-edge technology and solutions that enhance patient care, improve surgical outcomes, and streamline hospital operations. With a commitment to innovation and quality, Stryker plays a pivotal role in the medical industry, helping healthcare providers deliver effective treatment and improve the quality of life for patients around the world. Read More
Shares of medical technology company Stryker (NYSE:SYK) fell 2.9% in the afternoon session after it reported underwhelming earnings. Stryker's revenue grew 10.2% year on year to $6.06 billion, meeting expectations, while its adjusted earnings per share of $3.19 topped consensus estimates. Despite these positive headline numbers and a slight lift in its full-year earnings guidance, investors appeared to focus on a decline in profitability. The company's operating margin contracted to 18.7% from 19.7% in the same period last year. This compression in margins likely concerned shareholders, suggesting that the market was hoping for a stronger bottom-line performance.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Medical technology company Stryker (NYSE:SYK) met Wall Streets revenue expectations in Q3 CY2025, with sales up 10.2% year on year to $6.06 billion. Its non-GAAP profit of $3.19 per share was 1.9% above analysts’ consensus estimates.
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.
Medical technology company Stryker (NYSE:SYK) met Wall Streets revenue expectations in Q3 CY2025, with sales up 10.2% year on year to $6.06 billion. Its non-GAAP profit of $3.19 per share was 1.9% above analysts’ consensus estimates.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Stryker's Q3 2025 results were mixed: EPS beat estimates but revenue slightly missed. Shares fell as the market digested the strong earnings against the updated full-year guidance.
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Intuitive Surgical (NASDAQ: ISRG), the global leader in robotic-assisted surgery, announced a robust third quarter for 2025, sending its stock soaring as investors cheered impressive financial results and strong adoption of its latest da Vinci 5 surgical system. The company's report, released on October 21, 2025, showcased significant revenue and
The Death Cross is something you never want to see on a stock you own. Take caution with these three companies that recently were visited by this scary signal.
Stryker (NYSE:SYK), a global leader in medical technologies, will showcase new additions to its trauma offerings at the Orthopaedic Trauma Association (OTA) Annual Meeting, October 15–18, in Phoenix, Ariz. (booth #601). The company will highlight upcoming expansions to its nailing and plating platforms.
